Anthera Pharmaceuticals Stock Net Income
Anthera Pharmaceuticals fundamentals help investors to digest information that contributes to Anthera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Anthera Pink Sheet. The fundamental analysis module provides a way to measure Anthera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anthera Pharmaceuticals pink sheet.
Anthera |
Anthera Pharmaceuticals Company Net Income Analysis
Anthera Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Anthera Pharmaceuticals Net Income | (26.87 M) |
Most of Anthera Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anthera Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Anthera Pharmaceuticals reported net income of (26.87 Million). This is 107.87% lower than that of the Biotechnology sector and 138.37% lower than that of the Health Care industry. The net income for all United States stocks is 104.71% higher than that of the company.
Anthera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anthera Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Anthera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Anthera Pharmaceuticals by comparing valuation metrics of similar companies.Anthera Pharmaceuticals is currently under evaluation in net income category among its peers.
Anthera Fundamentals
| Return On Equity | -5.69 | ||||
| Return On Asset | -1.42 | ||||
| Current Valuation | (7.47 M) | ||||
| Shares Outstanding | 26.18 M | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | (0.20) X | ||||
| Price To Book | 0.11 X | ||||
| Gross Profit | (28.49 M) | ||||
| EBITDA | (26.59 M) | ||||
| Net Income | (26.87 M) | ||||
| Cash And Equivalents | 8.09 M | ||||
| Cash Per Share | 0.31 X | ||||
| Debt To Equity | 1.61 % | ||||
| Current Ratio | 3.30 X | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (36.9 M) | ||||
| Short Ratio | 2.09 X | ||||
| Earnings Per Share | (1.76) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 21 | ||||
| Beta | -108.04 | ||||
| Market Capitalization | 617.83 K | ||||
| Total Asset | 3.67 M | ||||
| Retained Earnings | (436.8 M) | ||||
| Working Capital | 39.39 M | ||||
| Current Asset | 47.86 M | ||||
| Current Liabilities | 8.47 M | ||||
| Net Asset | 3.67 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Anthera Pink Sheet
If you are still planning to invest in Anthera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Anthera Pharmaceuticals' history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |